For the Inventor, By the Inventor

Enter assignee name

Oss, Netherlands

Acerta Pharma B.v.

USPTO Granted Patents = 21

EPO Patents = 10

Forward Citations = 32

Loading Chart...

Loading Chart...

51 inventors (with patents filed for the assignee):

Tjeerd Barf (15 out of 23 patents)

Ahmed Hamdy (10 out of 10 patents)

Raquel Izumi (10 out of 10 patents)

4. Allard Kaptein (9 out of 13 patents)

5. Brian Lannutti (8 out of 18 patents)

6. Todd Covey (8 out of 9 patents)

7. Jerry B Evarts (8 out of 27 patents)

8. Wayne Philip Rothbaum (8 out of 64 patents)

9. Dave Johnson (7 out of 7 patents)

10. Roger G Ulrich (7 out of 12 patents)

11. Fritz Blatter (5 out of 57 patents)

12. Tim Ingallinera (5 out of 5 patents)

13. Cecile Krejsa (5 out of 10 patents)

14. Edwin Aret (5 out of 14 patents)

15. Saskia Verkaik (2 out of 2 patents)

21 patents: Sort by Forward Citations

1. 12448387 - Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide (2025-10-21),

2. 12263164 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2025-04-01),

3. 12024520 - Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide (2024-07-02),

4. 11820777 - Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide (2023-11-21),

5. 11771696 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2023-10-03),

6. 11654143 - Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor (2023-05-23),

7. 11590167 - Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors (2023-02-28),

8. 11166951 - Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor (2021-11-09),

9. 11110088 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase (2021-09-07),

10. 11090302 - Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor (2021-08-17),

11. 11059829 - Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate (2021-07-13),

12. 10858364 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase (2020-12-08),

13. 10736893 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase (2020-08-11),

14. 10640509 - Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma (2020-05-05),

15. 10328080 - Therapeutic combination of PI3K inhibitor and a BTK inhibitor (2019-06-25),

Acerta Pharma B.V. is a biopharmaceutical company focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company specializes in targeted covalent drug discovery and has developed a pipeline of potential therapies that selectively and irreversibly inhibit pathways that drive disease. Acerta Pharma is committed to improving patient outcomes through groundbreaking research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

21 Patents

#3 in Oss

#338 in Netherlands

#29,076 in the World

Oss, Netherlands

Acerta Pharma B.v.

Forward Citations = 32

51 inventors:

Tjeerd Barf (15 out of 23 patents)

Ahmed Hamdy (10 out of 10 patents)

Raquel Izumi (10 out of 10 patents)

4. Allard Kaptein (9 out of 13 patents)

5. Brian Lannutti (8 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…